Project Grant R33CA302206
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $368K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Leland Stanford Junior University totals $170,376.00 and is focused on developing a rapid, label-free, and cost-effective technique for Chimeric Antigen Receptor (CAR) T cell quantification in patient blood using Surface Enhanced Raman Spectroscopy (SERS) and Machine Learning (ML). The key products and services to be delivered under this award include: Optimizing a SERS...
- This Project Grant award from the Department of Health and Human Services National Institutes of Health (CFDA 93.310 Trans-NIH Research Support) provides $1,400,954.00 to The Leland Stanford Junior University to conduct research on combinatorial engineering of multicellular synthetic immunotherapy systems. The research program aims to: (1) co-optimize chimeric antigen receptors (CARs) and synthetic cytokine receptors (SCRs) to enhance anti-tumor immune cell function; (2) co-engineer T cells,...
- This federal Project Grant award of $640,522 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Leland Stanford Junior University supports research to elucidate how microbial microproteins modulate macrophage function, a critical coordinator of tumor immune response. The project aims to carry out high-throughput screens of thousands of microbial macromolecules to identify those that directly modulate macrophages, with the goal of enhancing cancer immunotherapy...
- This $414,803 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the Massachusetts Institute of Technology (MIT) to develop improved T cell receptor (TCR) engineering strategies for TCR-T cell cancer immunotherapy. The key products and services to be delivered under this grant include: Implementing high-throughput library screens of TCR constant region variants to identify mutations that can improve TCR signaling strength, with...
- The National Institutes of Health, National Cancer Institute awarded a $140,433 Project Grant to The Leland Stanford Junior University under the Cancer Research Manpower (CFDA 93.398) program. The award will be used to generate CD19.28Z chimeric antigen receptor (CAR) T cells in vivo using a Programmable Antibody-mediated Cellular Knock-in of T cells (PACK-IT) system. The goals are to optimize the PACK-IT system, compare the resulting PACK-IT CAR-T cells to conventionally manufactured CAR-T...
- The Leland Stanford Junior University was awarded a $1,108,391.72 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) with a project period from January 1, 2025 to December 31, 2027. The grant supports research to define the most therapeutically relevant CAR T cell subsets in patients with large B cell lymphoma (LBCL) and overcome immune suppression mechanisms of resistance to CAR T cell therapy. Key research activities include following...
- This federal Project Grant award of $672,371.00 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research at Yale University to develop ultra-sensitive mass spectrometry-based immunopeptidomics using digital microfluidics. The project aims to improve the identification of tumor-specific antigens (TSAs) to support the development of effective cancer immunotherapies. The award has a performance period from September 1, 2025...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $135,594.00 to The Leland Stanford Junior University to develop novel pharmacological approaches to rewire oncogenic gene expression and induce cancer cell death. The primary objectives are to: Develop small molecule chemical inducers of proximity (CIPs) that can potently activate pro-apoptotic gene expression and kill aggressive leukemias driven by MLL gene translocations. This will...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Pumpkinseed Technologies Inc. for $353,204 supports the development and demonstration of a novel technology called Cell-MAPP. The goal of this Phase I SBIR project is to create the first system capable of continuously monitoring the state transitions of individual T cells in response to antigen exposure. Cell-MAPP will utilize antigen-multimer barcoding and single-cell TCR sequencing to connect...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the University of California, San Francisco (UCSF) to genetically engineer myeloid cells, including macrophages and dendritic cells, for the treatment of solid tumors. The $0.00 award, with a project period from August 1, 2025 to July 31, 2028, aims to apply advanced genetic engineering tools to reprogram myeloid cells and enhance their tumoricidal activities and resistance to...